Order Article Reprints

Cavalcanti F, Gonzalez-Rey E, Delgado M, Falo CP, Mestre L, Guaza C, O’Valle F, Lufino MMP, Xaus J, Mascaró C, et al. Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022; 14(7):1420. https://doi.org/10.3390/pharmaceutics14071420

Cavalcanti, Fernando, Elena Gonzalez-Rey, Mario Delgado, Clara P. Falo, Leyre Mestre, Carmen Guaza, Francisco O’Valle, Michele M. P. Lufino, Jordi Xaus, Cristina Mascaró, and et al. 2022. "Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis" Pharmaceutics 14, no. 7: 1420. https://doi.org/10.3390/pharmaceutics14071420

Cavalcanti, F., Gonzalez-Rey, E., Delgado, M., Falo, C. P., Mestre, L., Guaza, C., O’Valle, F., Lufino, M. M. P., Xaus, J., Mascaró, C., Lunardi, S., Sacilotto, N., Dessanti, P., Rotllant, D., Navarro, X., Herrando-Grabulosa, M., Buesa, C., & Maes, T. (2022). Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics, 14(7), 1420. https://doi.org/10.3390/pharmaceutics14071420